T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias

References

• Alekshun TJ, Sokol L. Diseases of large granular lymphocytes. Cancer Control 2007;14:141–150.
   PubMedGoogle Scholar
• Zhang R, Shah MV, Loughran TP Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol 2010;28:105–117.
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist 2006;11:263–273.
   PubMed Web of Science ®Google Scholar
• Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007;25:171–192.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Kadin ME, Starkebaum G, . Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985;102:169–175.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, . Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989;42:567–584.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993;82:1–14.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994;84:2164–2170.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, . World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011;117:2764–2774.
   PubMed Web of Science ®Google Scholar
• Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789–795.
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Loughran TP Jr. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma 2009;9(Suppl. 3):S244–S253.
   PubMedGoogle Scholar
• Smyth MJ, Kelly JM, Sutton VR, . Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001;70:18–29.
   PubMed Web of Science ®Google Scholar
• Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004;9:247–258.
   PubMed Web of Science ®Google Scholar
• Freimark B, Lanier L, Phillips J, Quertermous T, Fox R. Comparison of T cell receptor gene rearrangements in patients with large granular T cell leukemia and Felty's syndrome. J Immunol 1987;138: 1724–1729.
   PubMed Web of Science ®Google Scholar
• Starkebaum G, Loughran TP Jr, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1997;40:624–626.
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Sivakumaran M, Snowden N, . The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty's syndrome. Arthritis Rheum 1994;37:1326–1330.
   PubMed Web of Science ®Google Scholar
• Liu X, Loughran TP Jr. The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol 2011;18:254–259.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Starkebaum G, Kidd P, Neiman P. Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1988;31:31–36.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994;84:1620–1627.
   PubMed Web of Science ®Google Scholar
• Gentile TC, Loughran TP Jr. Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia. Leuk Lymphoma 1996;23:405–408.
   PubMed Web of Science ®Google Scholar
• Babel N, Brestrich G, Gondek LP, . Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes. J Am Soc Nephrol 2009;20:344–352.
   PubMed Web of Science ®Google Scholar
• O'Keefe CL, Plasilova M, Wlodarski M, . Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol 2004;172:1960–1969.
   PubMed Web of Science ®Google Scholar
• Ryan DK, Alexander HD, Morris TC. Routine diagnosis of large granular lymphocytic leukaemia by Southern blot and polymerase chain reaction analysis of clonal T cell receptor gene rearrangement. Mol Pathol 1997;50:77–81.
   PubMedGoogle Scholar
• Beck RC, Stahl S, O'Keefe CL, Maciejewski JP, Theil KS, Hsi ED. Detection of mature T-cell leukemias by flow cytometry using anti- T-cell receptor V beta antibodies. Am J Clin Pathol 2003;120:785–794.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002;99:268–274.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Loughran TP Jr. Survival signals in leukemic large granular lymphocytes. Semin Hematol 2003;40:213–220.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Coyle T, Sherman MP, . Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood 1992;80:1116–1119.
   PubMed Web of Science ®Google Scholar
• Oshimi K, Yamada O, Kaneko T, . Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 1993;7:782–788.
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JC, Liu HS, Man C, Kwong YL. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature. Br J Haematol 2002;116: 598–600.
   PubMed Web of Science ®Google Scholar
• Parkman R. Human graft-versus-host disease. Immunodefic Rev 1991;2:253–264.
   PubMedGoogle Scholar
• Saravanan V, Hamilton J. Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin Pharmacother 2002;3:845–856.
   PubMedGoogle Scholar
• Groff GD, Shenberger KN, Wilke WS, Taylor TH. Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 1983;12:333–347.
   PubMed Web of Science ®Google Scholar
• Balint GP, Balint PV. Felty's syndrome. Best Pract Res Clin Rheumatol 2004;18:631–645.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:212–217.
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003;40:185–195.
   PubMed Web of Science ®Google Scholar
• Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990;4:2441–2452.
   PubMed Web of Science ®Google Scholar
• Tsukamoto T, Haile WH, McGuire JJ, Coward JK. Mechanism-based inhibition of human folylpolyglutamate synthetase: design, synthesis, and biochemical characterization of a phosphapeptide mimic of the tetrahedral intermediate. Arch Biochem Biophys 1998;355: 109–118.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003;62: 4–9.
   PubMed Web of Science ®Google Scholar
• Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989;32:770–775.
   PubMed Web of Science ®Google Scholar
• McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850–1856.
   PubMed Web of Science ®Google Scholar
• West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997;23:883–915.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, . Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532–2535.
   PubMed Web of Science ®Google Scholar
• Lamy T, Drenou B, Fardel O, . Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol 1998;100:509–515.
   PubMed Web of Science ®Google Scholar
• Battiwalla M, Melenhorst J, Saunthararajah Y, . HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 2003;123:449–453.
   PubMed Web of Science ®Google Scholar
• Osuji N, Matutes E, Tjonnfjord G, . T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer 2006;107:570–578.
   PubMed Web of Science ®Google Scholar
• Sood R, Stewart CC, Aplan PD, . Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998;91:3372–3378.
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol 2003;4:289–296.
   PubMedGoogle Scholar
• Park TS, Cheong JW, Song J, Choi JR. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res 2009;33:1001–1004.
   PubMed Web of Science ®Google Scholar
• Shimodaira S, Ishida F, Kobayashi H, Mahbub B, Kawa-Ha K, Kitano K. The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. Br J Haematol 1995;90:578–584.
   PubMed Web of Science ®Google Scholar
• Zambello R, Semenzato G. Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes. Semin Hematol 2003;40:201–212.
   PubMed Web of Science ®Google Scholar
• Kawa-Ha K, Ishihara S, Ninomiya T, . CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989;84:51–55.
   PubMed Web of Science ®Google Scholar
• Hart DN, Baker BW, Inglis MJ, . Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood 1992;79:2116–2123.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kishimoto T, Inoue M, . Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003;31:105–111.
   PubMed Web of Science ®Google Scholar
• Stromberg PC. Large granular lymphocyte leukemia in F344 rats. Model for human T gamma lymphoma, malignant histiocytosis, and T-cell chronic lymphocytic leukemia. Am J Pathol 1985;119:517–519.
   PubMed Web of Science ®Google Scholar
• Stromberg PC, Vogtsberger LM, Marsh LR, Wilson FD. Pathology of the mononuclear cell leukemia of Fischer rats. II. Hematology. Vet Pathol 1983;20:709–717.
   PubMed Web of Science ®Google Scholar
• Thomas J, Haseman JK, Goodman JI, Ward JM, Loughran TP Jr, Spencer PJ. A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment. Toxicol Sci 2007;99:3–19.
   PubMed Web of Science ®Google Scholar
• Liu X, Ryland L, Yang J, . Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010;116:4192–4201.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406–415.
   PubMed Web of Science ®Google Scholar
• Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001;1:50–58.
   PubMedGoogle Scholar
• Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 2004;1:186–192.
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T, . Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002;100:1449–1453.
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Irby R, . Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008;112:770–781.
   PubMed Web of Science ®Google Scholar
• Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9:162–176.
   PubMed Web of Science ®Google Scholar
• Park JH, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta 2006;1758:2133–2138.
   PubMed Web of Science ®Google Scholar
• Kothapalli R, Kusmartseva I, Loughran TP. Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta 2002;1579:117–123.
   PubMed Web of Science ®Google Scholar
• Niedernberg A, Blaukat A, Schoneberg T, Kostenis E. Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor. Br J Pharmacol 2003;138:481–493.
   PubMed Web of Science ®Google Scholar
• Walzer T, Chiossone L, Chaix J, . Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337–1344.
   PubMed Web of Science ®Google Scholar
• Spiegel S, Cuvillier O, Edsall LC, . Sphingosine-1-phosphate in cell growth and cell death. Ann NY Acad Sci 1998;845:11–18.
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84–105.
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother 2011;11:165–183.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, . Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883–897.
   PubMed Web of Science ®Google Scholar
• Strelow A, Bernardo K, Adam-Klages S, . Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000;192:601–612.
   PubMed Web of Science ®Google Scholar
• Samsel L, Zaidel G, Drumgoole HM, . The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004;58:382–393.
   PubMed Web of Science ®Google Scholar
• Bleicher RJ, Cabot MC. Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 2002;1585:172–178.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie KM, Yang GQ, . GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line. Cancer Chemother Pharmacol 2010;66:433–439.
   PubMed Web of Science ®Google Scholar
• Basu S, Kaufman B, Roseman S. Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J Biol Chem 1968;243:5802–5804.
   PubMed Web of Science ®Google Scholar
• Messner MC, Cabot MC. Glucosylceramide in humans. Adv Exp Med Biol 2010;688:156–164.
   PubMed Web of Science ®Google Scholar
• Spinedi A, Bartolomeo SD, Piacentini M. Apoptosis induced by N-hexanoylsphingosine in CHP-100 cells associates with accumulation of endogenous ceramide and is potentiated by inhibition of glucocerebroside synthesis. Cell Death Differ 1998;5:785–791.
   PubMed Web of Science ®Google Scholar
• Conway EM, Pollefeyt S, Steiner-Mosonyi M, . Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002;123:619–631.
   PubMed Web of Science ®Google Scholar
• Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117–1127.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337–346.
   PubMed Web of Science ®Google Scholar
• Kim YH, Lee DH, Jeong JH, Guo ZS, Lee YJ. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 2008;75:1946–1958.
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37–40.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Wei S, . ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 2004; 23:9220–9229.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Sokol L, Chen X, . Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008;112:4694–4698.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6:671–679.
   PubMed Web of Science ®Google Scholar
• Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006;103:10151–10152.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Liu JH, Catlett-Falcone R, . Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107: 351–362.
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257–262.
   PubMed Web of Science ®Google Scholar
• Jones RG, Elford AR, Parsons MJ, . CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 2002;196: 335–348.
   PubMed Web of Science ®Google Scholar
• Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006;107:4834–4840.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283–1316.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Nyland SB, . Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010;115:51–60.
   PubMed Web of Science ®Google Scholar
• Zambello R, Trentin L, Facco M, . Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Cancer Res 1995;55:6140–6145.
   PubMed Web of Science ®Google Scholar
• Wlodarski MW, O'Keefe C, Howe EC, . Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 2005;106:2769–2780.
   PubMed Web of Science ®Google Scholar
• Wlodarski MW, Nearman Z, Jankowska A, . Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol 2008;83:589–601.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Sherman MP, Ruscetti FW, . Prototypical HTLV-I/II infection is rare in LGL leukemia. Leuk Res 1994;18:423–429.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Hadlock KG, Perzova R, . Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol 1998;101:318–324.
   PubMed Web of Science ®Google Scholar
• Nearman ZP, Wlodarski M, Jankowska AM, . Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 2007; 136:237–248.
   PubMed Web of Science ®Google Scholar